Search 

We are a clinical stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. We are focused on harnessing powerful, untapped biology underlying major diseases to develop transformative therapeutics for patients.

The North American Representative Office of Shenzhen, P. R. China (NAROS) is a U.S. based, business service provider representing the City of Shenzhen, China´s first Special Economic Zone. Directly sponsored by the Shenzhen Municipal Government and Invest Shenzhen, NAROS offers guidance and consultation to North American companies wishing to enter the Chinese market by means of direct investment within in the City of Shenzhen, as well as to Shenzhen-based companies looking to enter the North American market.

Top MNC

A specialty company located in NJ focusing developing 505b2s and complex generics

Novodiax has develop a technology platform and product line that address unmet needs for rapid and accurate cancer diagnosis, including rapid intraoperative diagnosis for surgical treatments of cancers, rapid presurgical cancer diagnosis through biopsy specimens (Rapid On-Site Evaluation, ROSE), rapid disease diagnosis through liquid biopsy specimens and novel cancer biomarker’s based companion diagnostics (CDx).

Novodiax pioneered a 10-minute ihcDirectTM IHC detection for frozen section technology, which significantly saves time and reduces reagent consumption and costs with easy to use by reducing steps from traditional protocols. This innovated technology has removed many of the time constraining barriers that once prevented application of IHC stains in intraoperative diagnosis and Mohs surgery labs.
Novodiax also provides multiplex IHC detection which accelerates turnaround time, increases instrument productivity and reduces reagent consumption.

In summary Novodiax enjoys the following major strength
1- Novodiax currently offers a 10 min IHC product line that can be used for intraoperative evaluation of frozen tissues and for Rapid On-Site Evaluation (ROSE) of biopsy specimens.
2- Novodiax will launch in Q4 2020 an advanced automation system including a rapid compact IHC stainer and a superfast FFPE tissue pre-treatment device along with tens of ihcDirect® IHC reagents. This affordable system is a perfect solution for any situation where a rapid turnaround time is needed, such as, the rush cases using FFPE tissues in large medical centers. Our 10 min intraoperative and ROSE protocols will be available on the system too.
3- Novodiax products have already been optimized for Leica staining instruments and can be optimized for all automated staining platforms in the market.
4- The rapid turnaround time of Novodiax’s reagents and instruments offers a natural advantage for multiplex applications.

NxR Biotechnologies is a boutique global consulting firm assisting life science companies and academic institutions conduct business development or investment initiatives. Particularly, NxR provides Looking for services for performing strategic, scientific, and commercial assessments; writing business plans; gathering competitive intelligence; and implementing entrepreneurship projects, partnership and in/Licensing-out of conventional or regenerative medicine products, and commercialization deals. Areas of focus encompass the pharmaceutical industry and the white biotechnology industry. In the pharmaceutical industry, NxR focuses on cell-based and gene-based therapeutics, nucleic acid therapeutics, and biologics, in oncology, neurodegenerative diseases, inflammation, and rare diseases. In the white biotechnology industry, areas of specialization comprise sustainable chemicals including biomass conversion, biofuels, and polymers, as well as high value-added fermentation products including amino acids, proteins, and pharmaceuticals. NxR's track record comprises projects with big pharmas, biotechs, generics companies, financial investors, CROs, academia, and start-ups.